Research indicates that PLGA nanoparticles containing tumor antigens or immune adjuvants can foster antigen-specific CD4+ T-cell proliferation and cytokine release, thereby intensifying the Th1-mediated anti-tumor response. Here, CD4 is linked to neoplasm.